HLB Life Science Co.,Ltd. stock analysis
Want to see KR:067630 full AI Analyst Report?
HLB Life Science Co.,Ltd. (067630) Stock Price & Analysis
067630 Stock Chart & Stats
- Day’s Range
- KRW 2,290.00 - KRW 2,365.00
- 52-Week Range
- KRW 1,608.00 - KRW 5,330.00
- Previous Close
- KRW 2,345.00
- Volume
- N/A
- Average Volume (3M)
- 328.19K
- Market Cap
- KRW 286.34B
- Enterprise Value
- KRW 547.93B
- Total Cash (Recent Filing)
- KRW 13.88B
- Total Debt (Recent Filing)
- KRW 160.36B
- Price to Earnings (P/E)
- ―
- Beta
- 0.52
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Equity Base
A meaningful equity base provides some financial resilience and gives the company a larger capital cushion against operating losses. Although that cushion is being pressured, it may still support ongoing R&D and commercialization efforts while management works to restore profitability.
Prior Earnings Recovery
The 2024 profit and modest revenue growth demonstrate that the business has at least temporarily achieved improved operating outcomes. While the recovery was not sustained in 2025, this history indicates potential earnings sensitivity to successful products, cost control, or commercialization progress.
Non-Cash Loss Component
Free cash flow being less negative than net income in some periods suggests that reported losses are not entirely matched by immediate cash outflows. This does not remove the funding challenge, but it may reduce the pace at which accounting losses consume available resources.
Bears Say
Revenue And Profit Volatility
Sharp revenue contraction and the reversal from profit to a very large loss indicate that the current business model lacks stable earnings power. Persistently inconsistent margins, including negative gross margins in most years, could limit reinvestment and make future performance highly dependent on successful recovery.
Persistent Cash Burn
Sustained negative operating and free cash flow means the company is not currently self-financing its activities. Continued cash burn increases reliance on financing or existing balance-sheet resources, potentially limiting the funds available for drug development, commercialization, and other strategic priorities.
Worsening Leverage
Higher debt relative to equity reduces financial flexibility while the company is already generating losses and negative cash flow. The simultaneous decline in equity and sharply negative 2025 return on equity suggests that the capital base is under pressure and may provide diminishing protection over time.
067630 FAQ
What was HLB Life Science Co.,Ltd.’s price range in the past 12 months?
What is HLB Life Science Co.,Ltd.’s market cap?
When is HLB Life Science Co.,Ltd.’s upcoming earnings report date?
How were HLB Life Science Co.,Ltd.’s earnings last quarter?
Is HLB Life Science Co.,Ltd. overvalued?
Does HLB Life Science Co.,Ltd. pay dividends?
What is HLB Life Science Co.,Ltd.’s EPS estimate?
How many shares outstanding does HLB Life Science Co.,Ltd. have?
What happened to HLB Life Science Co.,Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HLB Life Science Co.,Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
HLB Life Science Co.,Ltd.
HLB Life Science Co Ltd specializes in a range of energy solutions, encompassing both traditional services and renewable power initiatives. Its offerings include advanced energy-saving facilities, systems for recovering condensing water, combined heat and power (cogeneration) setups, and the development of solar energy projects. Complementing its established energy operations, the company has also diversified its investments into novel pharmaceutical development and the broader medical field.
- Sector
- General
- Industry
- Renewable Utilities
- Address
- KR
HLB Life Science Co.,Ltd. (067630) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |

